Evidence map›Paper›PMID 28646041›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2017

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.

Maher G Nawaf, Maria H Ulvmar, David R Withers, Fiona M McConnell, Fabrina M Gaspal, Gwilym J Webb, Nick D Jones, Hideo Yagita, James P Allison, Peter J L Lane

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. CD30Cancer immunology, immunotherapy : CII · 2021
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Maher G NawafInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Maria H UlvmarDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-9050-0978
David R WithersInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Fiona M McConnellInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0001-8041-1771
Fabrina M GaspalInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Gwilym J WebbInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom.ORCID 0000-0002-0710-5644
Nick D JonesInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Hideo YagitaDepartment of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan; and.
James P AllisonDepartment of Immunology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030.
Peter J L LaneInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, United Kingdom; p.j.l.lane@bham.ac.uk.ORCID 0000-0002-0600-768X
NIHR Birmingham Biomedical Research Centre · GBJuntendo University · JPThe University of Texas MD Anderson Cancer Center · USUppsala University · SE

Funding

Medical Research Council MR/L000210/1Medical Research Council MR/M001911/1Wellcome Trust 110199/Z/15/Z
6 · The paper itself

Abstract

Although strategies that block FOXP3-dependent regulatory T cell function (CTLA4 blockade) and the inhibitory receptor PD1 have shown great promise in promoting antitumor immune responses in humans, their widespread implementation for cancer immunotherapy has been hampered by significant off-target autoimmune side effects that can be lethal. Our work has shown that absence of OX40 and CD30 costimulatory signals prevents CD4 T cell-driven autoimmunity in Foxp3-deficient mice, suggesting a novel way to block these side effects. In this study, we show that excellent antitumor CD8 T cell responses can be achieved in Foxp3

Indexed as

AutoimmunityAnimalsCD30 LigandCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCTLA-4 AntigenForkhead Transcription FactorsImmunotherapyLigandsLymphocyte ActivationMiceMice, KnockoutNeoplasmsProgrammed Cell Death 1 ReceptorReceptors, OX40T-Lymphocytes, RegulatoryCD30 LigandCTLA-4 AntigenCtla4 protein, mouseForkhead Transcription FactorsFoxp3 protein, mouseLigandsProgrammed Cell Death 1 ReceptorReceptors, OX40

Identifiers

PMID28646041
PMCPMC5523579
OpenAlexW2723503166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.